Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.37 |
| ▸ | CCR9 | P51686 | 1/20 | 0.35 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | TKT | P29401 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10299407 | 0.90 | TLR7 (0.38) | ADORA2AADORA1CYP11B1CYP11B2TLR7 | |
| SCHEMBL2060420 | 0.89 | TLR7 (0.40) | ADORA2AADORA1CYP11B1CYP11B2TLR7 | |
| SCHEMBL10309723 | 0.84 | ADORA2A (0.44) | ADORA2AADORA1TLR7TMIGD3ADORA2B | |
| SCHEMBL2060257 | 0.83 | CYP11B1 (0.41) | CYP11B1CYP11B2 | |
| SCHEMBL5474204 | 0.82 | TLR7 (0.46) | ADORA2AADORA1TLR7TMIGD3ADORA2B | |
| SCHEMBL10174470 | 0.78 | TSHR (0.40) | ADORA2AADORA1TLR7 | |
| SCHEMBL2060146 | 0.76 | TLR7 (0.42) | ADORA2AADORA1CYP11B1CYP11B2TLR7 | |
| SCHEMBL2060338 | 0.75 | TLR7 (0.52) | TLR7 | |
| SCHEMBL2060646 | 0.75 | TLR7 (0.48) | ADORA2AADORA1CYP11B1CYP11B2TLR7 | |
| SCHEMBL2060449 | 0.74 | TLR7 (0.51) | ADORA2AADORA1TLR7TMIGD3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-12 | — | — | US | disclosed |
| EP-1550662-B1 | ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-8148371-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-8148371-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-8148371-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-7754728-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
| US-7754728-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
| US-7754728-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
| US-20060052403-A1 | Novel adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2006-03-09 | — | — | US | disclosed |
| EP-1550662-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, P2RY10, HRH4 | ADORA2A 6/4885ADORA1 1/4885CYP11B1 53/4885 |
| US-20060052403-A1 | Novel adenine compound and use thereof | ADORA1, P2RY10, HRH4 | ADORA2A 6/4885ADORA1 1/4885CYP11B1 53/4885 |
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, HRH4, P2RY10 | ADORA2A 4/4885ADORA1 1/4885CYP11B1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.